HealthLynked Corp. (OTCQB: HLYK) has announced a strategic partnership with 3X4 Genetics to offer personalized genetic testing to its members, advancing its mission to provide tailored and predictive healthcare solutions. The collaboration will allow HealthLynked members to access 3X4 Genetics’ sophisticated genetic insights, empowering them to make informed health decisions and receive more personalized care. This partnership marks a key step in HealthLynked’s broader strategy of integrating cutting-edge technologies to improve healthcare outcomes and expand its service offerings.
To view the full press release, visit https://ibn.fm/GL0d6
About HealthLynked Corp.
HealthLynked Corp. is committed to improving global healthcare by facilitating the efficient exchange of medical information between patients and providers. The company’s network empowers members to actively manage their healthcare through a centralized and secure platform. For more information about HealthLynked Corp., please visit www.healthlynked.com.
NOTE TO INVESTORS: The latest news and updates relating to HealthLynked are available in the company’s newsroom at https://ibn.fm/HLYK
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
Co-Diagnostics (NASDAQ: CODX) announced that its Indian joint venture, CoSara Diagnostics Pvt. Ltd., has signed an agreement to expand…
Black Hawk Acquisition (Nasdaq: BKHA, BKHAU, BKHAR) announced that its proposed de-SPAC acquisition target, Vesicor Therapeutics Inc., has…
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases, announced that a comprehensive summary of clinical…
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases, was featured in the latest BioMedWire Podcast…
Annovis Bio (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company, announced a partnership with NeuroRPM…
Nutriband (NASDAQ: NTRB) announced that the Costa Rica Ministry of Health has approved its line of…